ALXO
ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
Wednesday, September 21, 2022 BiopharmaWatch Research 1 min read Key Takeaway: ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
Price reaction · baseline $10.99 (2022-09-20 close) · hit after-hours · clean, no other ALXO news in the window
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+102%
120-day peak, hindsight
Typical move
7.9%
average across 6 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ALX2004
Phase 1 · NSCLC (Advanced Non-small Cell Lung Cancer)
Full Press Release Details
ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference.